Takeda R&D Chief Touts Pipeline Revolution, 70% of Research Now in Non-Small Molecules

Takeda Pharmaceutical’s R&D transformation has brought about a revolutionary change to its pipeline as it has raised its innovation bar and diversified modalities, with the number of non-small molecule candidates now accounting for 70% of its research, R&D President Andy...read more